SpringerLink
Log in

Graves’ Disease and Toxic Nodular Goiter (Plummer’s Disease)

  • Chapter
  • First Online:
Endocrine Surgery Comprehensive Board Exam Guide

  • 1038 Accesses

Abstract

Hyperthyroidism is a set of disorders that involve excess synthesis and secretion of thyroid hormones by the thyroid gland, which leads to thyrotoxicosis. The most common forms of hyperthyroidism include diffuse toxic goiter (Graves’ disease), toxic multinodular goiter (Plummer’s disease), and a solitary toxic adenoma. The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Options for treatment of hyperthyroidism include antithyroid drugs, radioactive iodine therapy (the preferred treatment of hyperthyroidism among US thyroid specialists), or thyroidectomy. Massive thyroid enlargement with compressive symptoms, a suspicious nodule, Graves’ orbitopathy, and patient preference are indications for surgical treatment of thyrotoxicosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 106.99
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 139.09
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T-4 and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.

    Google Scholar 

  2. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.

    Article  PubMed  Google Scholar 

  3. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54(1–3):191–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65.

    Article  PubMed  Google Scholar 

  5. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252–65.

    Article  CAS  PubMed  Google Scholar 

  6. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014;311(15):1563–5.

    Article  CAS  PubMed  Google Scholar 

  7. Antonelli A, Ferrari SM, Ragusa F, et al. Graves’ disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387.

    Article  CAS  PubMed  Google Scholar 

  8. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168–99.

    CAS  PubMed  Google Scholar 

  9. Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall J. Reevaluation of the prevalences of serum autoantibodies reactive with “64-kd eye muscle proteins” in patients with thyroid-associated ophthalmopathy. Thyroid. 1998;8(2):175–9.

    Article  CAS  PubMed  Google Scholar 

  10. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.

    Article  CAS  PubMed  Google Scholar 

  12. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.

    Article  CAS  PubMed  Google Scholar 

  13. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2013;28(4):275–9.

    Article  Google Scholar 

  15. In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves’ disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209(2):170–9.

    Article  PubMed  Google Scholar 

  16. Masiello E, Veronesi G, Gallo D, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Investig. 2018;41(12):1425–32.

    Article  CAS  Google Scholar 

  17. Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97(7):2396–403.

    Article  CAS  PubMed  Google Scholar 

  18. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373–81.

    Article  CAS  PubMed  Google Scholar 

  19. Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology. The use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.

    Article  CAS  PubMed  Google Scholar 

  20. Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2012;95(1):201–8.

    Article  Google Scholar 

  21. Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  22. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves’ orbitopathy. Thyroid. 2010;20(7):785–93.

    Article  CAS  PubMed  Google Scholar 

  23. Bhargav PRK, Sabaretnam M, Kumar SC, Zwalitha S, Devi NV. Regression of ophthalmopathic exophthalmos in Graves’ disease after total thyroidectomy: a prospective study of a surgical series. Indian J Surg. 2017;79(6):521–6.

    Article  CAS  PubMed  Google Scholar 

  24. Lorenz K, Raffaeli M, Barczyński M, Lorente-Poch L, Sancho J. Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement. Langenbeck’s Arch Surg. 2020;405(4):401–25.

    Article  Google Scholar 

  25. Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O. The effect of preoperative Lugol’s iodine on intraoperative bleeding in patients with hyperthyroidism. Ann Med Surg (Lond). 2016;9:53–7.

    Google Scholar 

  26. Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves’ disease. Am J Surg. 2017;213(4):805–9.

    Article  PubMed  Google Scholar 

  27. Erbil Y, Ozluk Y, Giriş M, et al. Effect of Lugol’s solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2182–9.

    Article  CAS  PubMed  Google Scholar 

  28. Mercier F, Bonal M, Fanget F, et al. Does surgery without Lugol’s solution pretreatment for graves’ disease increase surgical morbidity? World J Surg. 2018;42(7):2123–6.

    Article  PubMed  Google Scholar 

  29. Jörtsö E, Lennquist S, Lundström B, Norrby K, Smeds S. The influence of remnant size, antithyroid antibodies, thyroid morphology, and lymphocytic infiltration on thyroid function after subtotal resection for hyperthyroidism. World J Surg. 1987;11(3):365–71.

    Article  PubMed  Google Scholar 

  30. Alsnea O, Clark OH. Treatment of Graves’ disease: the advantages of surgery. Endocrinol Metab Clin N Am. 2000;29(2):321–37.

    Article  Google Scholar 

  31. Barczyński M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Nowak W. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves’ disease with a 5-year follow-up. Br J Surg. 2012;99(4):515–22.

    Article  PubMed  Google Scholar 

  32. Maurer E, Maschuw K, Reuss A, et al. Total versus near-total thyroidectomy in Graves’ disease: results of the randomized controlled multicenter TONIG-trial. Ann Surg. 2019;270(5):755–61.

    Article  PubMed  Google Scholar 

  33. Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy. Cochrane Database Syst Rev. 2015;(11):CD010576.

    Google Scholar 

  34. Bobanga ID, McHenry CR. Treatment of patients with Graves’ disease and the appropriate extent of thyroidectomy. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101319.

    Article  PubMed  Google Scholar 

  35. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med. 1990;89(5):602–8.

    Article  CAS  PubMed  Google Scholar 

  36. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010;322(1–2):125–34.

    Article  CAS  PubMed  Google Scholar 

  37. Siegel RD, Lee SL. Toxic nodular goiter: toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin N Am. 1998;27(1):151–68.

    Article  CAS  Google Scholar 

  38. Krohn K, Führer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005;26(4):504–24.

    Article  CAS  PubMed  Google Scholar 

  39. Vitti P, Rago T, Tonacchera M, Pinchera A. Toxic multinodular goiter in the elderly. J Endocrinol Invest. 2002;25(10 suppl):16–18.

    Google Scholar 

  40. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(1):E1–8.

    Article  CAS  PubMed  Google Scholar 

  41. Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf). 2010;72(5):685–8.

    Google Scholar 

  42. Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol. 2011;77(1):146–51.

    Article  Google Scholar 

  43. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ. 2006;332(7554):1369–73.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415–20.

    Article  CAS  PubMed  Google Scholar 

  45. Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899–905.

    Article  CAS  PubMed  Google Scholar 

  46. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983;62(1):1–20.

    Article  CAS  Google Scholar 

  47. Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin N Am. 2007;36(3):617–56.

    Article  CAS  Google Scholar 

  48. van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Investig. 1992;15(11):797–800.

    Article  Google Scholar 

  49. Azizi F, Takyar M, Madreseh E, Amouzegar A. Treatment of toxic multinodular goiter: comparison of radioiodine and long-term methimazole treatment. Thyroid. 2019;29(5):625–30. https://doi.org/10.1089/thy.2018.0397.

    Article  CAS  PubMed  Google Scholar 

  50. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121(10):757–62.

    Article  CAS  PubMed  Google Scholar 

  51. Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159(12):1364–8.

    Google Scholar 

  52. Schiavo M, Bagnara MC, Camerieri L, et al. Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm. Endocrine. 2015;48(3):902–8.

    Article  CAS  PubMed  Google Scholar 

  53. Ríos A, Rodríguez JM, Balsalobre MD, Torregrosa NM, Tebar FJ, Parrilla P. Results of surgery for toxic multinodular goiter. Surg Today. 2005;35(11):901–6.

    Article  PubMed  Google Scholar 

  54. Schneider R, Randolph GW, Dionigi G, et al. International neural monitoring study group guideline 2018 part I: staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope. 2018;128(Suppl 3):S1–S17.

    Article  PubMed  Google Scholar 

  55. Miccoli P, Antonelli A, Iacconi P, Alberti B, Gambuzza C, Baschieri L. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow up. Surgery. 1993;114(6):1097–101.

    CAS  PubMed  Google Scholar 

  56. Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008;32(7):1313–24.

    Article  PubMed  Google Scholar 

  57. Ríos A, Rodríguez JM, Galindo PJ, Montoya MJ, Canteras M, Parrilla P. Surgical treatment of multinodular goiter in young patients. Endocrine. 2005;27(3):245–52.

    Article  PubMed  Google Scholar 

  58. Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg. 2008;32(7):1301–12.

    Article  PubMed  Google Scholar 

  59. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting in important decision. A cost-effectiveness analysis. Thyroid. 2004;14(11):933–45.

    Article  PubMed  Google Scholar 

  60. Barczyński M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Nowak W. Ten-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular non-toxic goiter. World J Surg. 2018;42(2):384–92.

    Article  PubMed  Google Scholar 

  61. Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53(3):157–60.

    Article  CAS  PubMed  Google Scholar 

  62. Alexopoulou O, Beguin C, Buysschaert M, et al. Predictive factors of thyroid carcinoma in non-toxic multinodular goiter. Acta Clin Belg. 2004;59(2):84–9.

    Article  CAS  PubMed  Google Scholar 

  63. Senyurek Giles Y, Tunca F, Boztepe H, Kapran Y, Terzioglu T, Tezelman S. The risk factors for malignancy in surgically treated patients for Graves’s disease, toxic multinodular goiter, and toxic adenoma. Surgery. 2008;144(6):1028–36.

    Article  PubMed  Google Scholar 

  64. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrine Surgery, Third Chair of General Surgery, Jagiellonian University – Medical College, Kraków, Poland

    Marcin Barczyński

  2. Clinical Ward of Surgery and Oncology, Gabriel Narutowicz Memorial Municipal Hospital, Kraków, Poland

    Marcin Barczyński

Authors
  1. Marcin Barczyński
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcin Barczyński .

Editor information

Editors and Affiliations

  1. Department of Surgery, Jersey Shore University Medical Center, Neptune, NJ, USA

    Alexander L. Shifrin

  2. Division of Endocrine and Metabolic Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

    Marco Raffaelli

  3. The Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology, Harvard Medical School, Boston, MA, USA

    Gregory W. Randolph

  4. Department of Surgery, Linkö** University, Linkö**, Sweden

    Oliver Gimm

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barczyński, M. (2021). Graves’ Disease and Toxic Nodular Goiter (Plummer’s Disease). In: Shifrin, A.L., Raffaelli, M., Randolph, G.W., Gimm, O. (eds) Endocrine Surgery Comprehensive Board Exam Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-84737-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84737-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84736-4

  • Online ISBN: 978-3-030-84737-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation